Anti-TNF therapy significantly improves the disease activity of RA, AS or PsA in the majority of the patients compared with conventional DMARDs [14,15], although the benefits become evident only when the biologic is combined with methotrexate, apart from the IL-6R blocker tocilizumab, which appears to be superior to methotrexate even in monotherapy [16]. Here, IL6R is linked to rheumatoid arthritis.